MX2015010339A - Inhibidores de helicasa-primasa para su uso en un metodo para tratar la enfermedad de alzheimer. - Google Patents
Inhibidores de helicasa-primasa para su uso en un metodo para tratar la enfermedad de alzheimer.Info
- Publication number
- MX2015010339A MX2015010339A MX2015010339A MX2015010339A MX2015010339A MX 2015010339 A MX2015010339 A MX 2015010339A MX 2015010339 A MX2015010339 A MX 2015010339A MX 2015010339 A MX2015010339 A MX 2015010339A MX 2015010339 A MX2015010339 A MX 2015010339A
- Authority
- MX
- Mexico
- Prior art keywords
- helicase
- disease
- primase inhibitors
- treating alzheimer
- infection
- Prior art date
Links
- 208000024827 Alzheimer disease Diseases 0.000 title abstract 7
- 239000003112 inhibitor Substances 0.000 title abstract 4
- 238000000034 method Methods 0.000 title abstract 3
- 208000037952 HSV-1 infection Diseases 0.000 abstract 3
- 102000013455 Amyloid beta-Peptides Human genes 0.000 abstract 1
- 108010090849 Amyloid beta-Peptides Proteins 0.000 abstract 1
- 238000009825 accumulation Methods 0.000 abstract 1
- 230000000840 anti-viral effect Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/426—1,3-Thiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A61P31/22—Antivirals for DNA viruses for herpes viruses
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Virology (AREA)
- Organic Chemistry (AREA)
- Neurosurgery (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Oncology (AREA)
- Hospice & Palliative Care (AREA)
- Communicable Diseases (AREA)
- Molecular Biology (AREA)
- Psychiatry (AREA)
- Biotechnology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP13154982 | 2013-02-12 | ||
| PCT/EP2014/052743 WO2014124978A2 (en) | 2013-02-12 | 2014-02-12 | Helicase-primase inhibitors for use in a method of treating alzheimer's disease |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2015010339A true MX2015010339A (es) | 2015-11-16 |
Family
ID=47709982
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2015010339A MX2015010339A (es) | 2013-02-12 | 2014-02-12 | Inhibidores de helicasa-primasa para su uso en un metodo para tratar la enfermedad de alzheimer. |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US20150374676A1 (OSRAM) |
| EP (1) | EP2956134A2 (OSRAM) |
| JP (1) | JP2016507546A (OSRAM) |
| KR (1) | KR20150119089A (OSRAM) |
| CN (1) | CN105101963A (OSRAM) |
| AU (1) | AU2014217962A1 (OSRAM) |
| BR (1) | BR112015019220A2 (OSRAM) |
| CA (1) | CA2898798A1 (OSRAM) |
| CL (1) | CL2015002241A1 (OSRAM) |
| EA (1) | EA201500836A1 (OSRAM) |
| IL (1) | IL240459A0 (OSRAM) |
| MX (1) | MX2015010339A (OSRAM) |
| PH (1) | PH12015501762A1 (OSRAM) |
| SG (1) | SG11201506153TA (OSRAM) |
| WO (1) | WO2014124978A2 (OSRAM) |
| ZA (1) | ZA201505243B (OSRAM) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2573085A1 (en) * | 2011-09-26 | 2013-03-27 | AiCuris GmbH & Co. KG | N-[5-(aminosulfonyl)-4methyl-1,3-thiazol-2-yl]-N-methyl-2-[4-(2-pyridinyl)phenyl] acetamide mesylate monohydrate having a specific particle size distribution range and a specific surface area range |
| TWI753972B (zh) * | 2016-11-28 | 2022-02-01 | 德商艾庫瑞斯公司 | N-[5-(胺基磺醯基)-4-甲基-1,3-噻唑-2-基]-n-甲基-2-[4-(2-吡啶基)-苯基]-乙醯胺之游離鹼的順丁烯二酸鹽，醫藥調配物、製造方法及其用途 |
| US11439608B2 (en) | 2017-09-25 | 2022-09-13 | Qun Lu | Roles of modulators of intersectin-CDC42 signaling in Alzheimer's disease |
| TW202038947A (zh) * | 2018-11-28 | 2020-11-01 | 德商創新分子有限責任公司 | 在與溶瘤病毒之組合療法中治療癌症的解旋酶引子酶抑制劑 |
| JP7720044B2 (ja) | 2020-11-19 | 2025-08-07 | グリアセルテック・インコーポレイテッド | ジダノシンを含む神経炎症性疾患の予防または治療用組成物 |
| JP2025530762A (ja) * | 2022-08-29 | 2025-09-17 | アセンブリー・バイオサイエンシーズ・インコーポレイテッド | ヘルペスウイルス用医薬組成物 |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DOP2000000109A (es) * | 1999-12-23 | 2002-08-30 | Gerald Kleymann | Derivados de tiazolilamida |
| DE102005014248A1 (de) * | 2005-03-30 | 2006-10-05 | Aicuris Gmbh & Co. Kg | Pharmazeutische Zubereitung von N-[5-(Aminosulfonyl)-4-methyl-1,3-thiazol-2-yl]-N-methyl-2-[4-(2-pyridinyl)phenyl]acetamid |
| US8299059B2 (en) * | 2009-10-30 | 2012-10-30 | Eli Lilly And Company | Crystalline compound and a process for its preparation |
| EP2573085A1 (en) | 2011-09-26 | 2013-03-27 | AiCuris GmbH & Co. KG | N-[5-(aminosulfonyl)-4methyl-1,3-thiazol-2-yl]-N-methyl-2-[4-(2-pyridinyl)phenyl] acetamide mesylate monohydrate having a specific particle size distribution range and a specific surface area range |
-
2014
- 2014-02-12 KR KR1020157024625A patent/KR20150119089A/ko not_active Withdrawn
- 2014-02-12 AU AU2014217962A patent/AU2014217962A1/en not_active Abandoned
- 2014-02-12 EA EA201500836A patent/EA201500836A1/ru unknown
- 2014-02-12 WO PCT/EP2014/052743 patent/WO2014124978A2/en not_active Ceased
- 2014-02-12 US US14/767,163 patent/US20150374676A1/en not_active Abandoned
- 2014-02-12 BR BR112015019220A patent/BR112015019220A2/pt not_active IP Right Cessation
- 2014-02-12 EP EP14703891.3A patent/EP2956134A2/en not_active Withdrawn
- 2014-02-12 JP JP2015556537A patent/JP2016507546A/ja not_active Withdrawn
- 2014-02-12 SG SG11201506153TA patent/SG11201506153TA/en unknown
- 2014-02-12 CN CN201480008550.6A patent/CN105101963A/zh active Pending
- 2014-02-12 MX MX2015010339A patent/MX2015010339A/es unknown
- 2014-02-12 CA CA2898798A patent/CA2898798A1/en not_active Abandoned
-
2015
- 2015-07-21 ZA ZA2015/05243A patent/ZA201505243B/en unknown
- 2015-08-09 IL IL240459A patent/IL240459A0/en unknown
- 2015-08-11 PH PH12015501762A patent/PH12015501762A1/en unknown
- 2015-08-11 CL CL2015002241A patent/CL2015002241A1/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| BR112015019220A2 (pt) | 2017-07-18 |
| WO2014124978A3 (en) | 2014-10-30 |
| CN105101963A (zh) | 2015-11-25 |
| EP2956134A2 (en) | 2015-12-23 |
| PH12015501762A1 (en) | 2015-11-09 |
| ZA201505243B (en) | 2017-11-29 |
| JP2016507546A (ja) | 2016-03-10 |
| SG11201506153TA (en) | 2015-09-29 |
| IL240459A0 (en) | 2015-09-24 |
| EA201500836A1 (ru) | 2016-02-29 |
| WO2014124978A2 (en) | 2014-08-21 |
| US20150374676A1 (en) | 2015-12-31 |
| CA2898798A1 (en) | 2014-08-21 |
| KR20150119089A (ko) | 2015-10-23 |
| WO2014124978A4 (en) | 2014-12-24 |
| AU2014217962A1 (en) | 2015-09-17 |
| CL2015002241A1 (es) | 2016-02-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PH12015501762A1 (en) | Helicase-primase inhibitors for use in a method of treating alzheimer's disease | |
| MX2016008688A (es) | Compuestos terapéuticos inhibidores. | |
| CO2017005034A2 (es) | Tratamiento de convulsiones con fosfatasa alcalina recombinante | |
| SI3068405T1 (sl) | Pirolo (1,2,f)(1,2,4)triazini uporabni za zdavljenje okužb z respiratornim sincicijskim virusom | |
| BR112016015236A2 (pt) | inibidores de serina/treonina quinase | |
| NZ746139A (en) | Methods for treating conditions associated with masp-2 dependent complement activation | |
| MX378283B (es) | Compuestos de n-((het)arilmetil)-heteroaril-carboxamidas como inhibidores de calicreina plasmatica. | |
| BR112018003526A2 (pt) | métodos de tratamento de doenças inflamatórias | |
| MX363689B (es) | Derivados de heterociclicos. | |
| JO3564B1 (ar) | ببتيدات وتركيبات لعلاج ضرر المفاصل | |
| IL278247B (en) | mct4 inhibitors to treat the disease | |
| EA201690513A1 (ru) | Комбинация ингибитора mek и ингибитора erk для применения в лечении гиперпролиферативных заболеваний | |
| EA201791101A1 (ru) | Способы лечения рассеянного склероза | |
| EA201792641A1 (ru) | Ингибитор оси igfbp3/tmem219 и диабет | |
| MX2017014782A (es) | Metodo para el tratamiento de enfermedad neurologica. | |
| MX382044B (es) | Oxabicicloheptanos y oxabicicloheptenos para el tratamiento de trastornos depresivos y de estrés. | |
| MX367707B (es) | Composiciones para uso en la prevencion y el tratamiento de enfermedades neurodegenerativas y dolor. | |
| EA201691057A1 (ru) | Новые способы лечения нейродегенеративных заболеваний | |
| EA201792124A1 (ru) | Биотин для лечения амиотрофического латерального склероза | |
| EP2854799A4 (en) | METHOD FOR TREATING INFECTION WITH SCEDOSPORIUM SPECIES | |
| AR108890A1 (es) | Inhibidores de la entrada del cmvh | |
| FR3017550B1 (fr) | Machine de traitement de dechets infectieux, notamment medicaux | |
| EA201990513A1 (ru) | АГОНИСТ PPARγ ДЛЯ ЛЕЧЕНИЯ ПОРАЖЕНИЙ КОСТЕЙ | |
| PH12017500492A1 (en) | Crystalline bace inhibitors | |
| PL3960195T3 (pl) | Engrailed do zastosowania w leczeniu stwardnienia zanikowego bocznego |